HKSE:06929'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.63 Med: 17.54 Max: 52.47
Current: 16.66
During the past 6 years, the highest EV-to-FCF of OrbusNeich Medical Group Holdings was 52.47. The lowest was 5.63. And the median was 17.54.
HKSE:06929's EV-to-FCF is ranked better than 66.06% of 386
companies
in the Medical Devices & Instruments industry
Industry Median: 24.165
vs HKSE:06929: 16.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of OrbusNeich Medical Group Holdings's EV-to-FCF
For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrbusNeich Medical Group Holdings's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where OrbusNeich Medical Group Holdings's EV-to-FCF falls into.
OrbusNeich Medical Group Holdings's current Enterprise Value is HK$1,021 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OrbusNeich Medical Group Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrbusNeich Medical Group Holdings (HKSE:06929) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
OrbusNeich Medical Group Holdings's PE Ratio (TTM) for today is calculated as:
OrbusNeich Medical Group Holdings's share price for today is HK$3.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OrbusNeich Medical Group Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.375.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
OrbusNeich Medical Group Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
OrbusNeich Medical Group Holdings Business Description
OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06929 has been successfully added to your 